Catalog No.
DHC15804
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
Hybridoma growth factor, BSF-2, IFN-beta-2, CDF, IL6, Interleukin-6, IL-6, B-cell stimulatory factor 2, Interferon beta-2, IFNB2, CTL differentiation factor
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P05231
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CDP 6038, CAS: 1007223-17-7
Clone ID
Olokizumab
[Anti-IL-6 : new therapeutic trends], PMID: 28703549
[Experience of olokizumab use in COVID-19 patients], PMID: 33720587
[IL-6 blockade], PMID: 27311186
Analysis of miRNA Expression in Patients with Rheumatoid Arthritis during Olokizumab Treatment, PMID: 33142700
Antibodies to watch in 2021, PMID: 33459118
Biosensing Cytokine IL-6: A Comparative Analysis of Natural and Synthetic Receptors, PMID: 32847008
Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling, PMID: 24670876
Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial, PMID: 26358841
Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study, PMID: 24641941
Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis, PMID: 32033937
IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future, PMID: 25648633
IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab, PMID: 24833786
Interleukin-6 blocking agents for treating COVID-19: a living systematic review, PMID: 33734435
Interleukin-6 inhibition in the management of non-infectious uveitis and beyond, PMID: 31523783
Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies, PMID: 34101570
Model-Based Optimal Design and Execution of the First-Inpatient Trial of the Anti-IL-6, Olokizumab, PMID: 24941311
Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study, PMID: 34344706
Probing binding mechanism of interleukin-6 and olokizumab: in silico design of potential lead antibodies for autoimmune and inflammatory diseases, PMID: 26982101
Profile of sarilumab and its potential in the treatment of rheumatoid arthritis, PMID: 28579757
Rheumatoid arthritis: new monoclonal antibodies, PMID: 29771256
Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study, PMID: 27129012
Targeting interleukin-6 for noninfectious uveitis, PMID: 26392750
For research use only. Not for human or drug use.
